The five growth metrics PE sponsors actually underwrite
Sponsors do not buy impressions. They buy predictable new-patient volume with a defensible cost curve. These are the five numbers that survive diligence.
What gets scrutinized
Across platform diligence, five metrics do the heavy lifting:
- Net new patients per location per month, reconciled to the PMS.
- Blended patient acquisition cost, by market and specialty.
- First-year patient value and retained value at 24 months.
- Appointment fill rate and no-show rate as a capacity proxy.
- Share-of-answer and review velocity as leading indicators.
Why dashboards fail diligence
Most portfolio dashboards aggregate platform-reported conversions from four ad accounts and a call tracker. Nothing reconciles to the chart. The moment a QoE team asks for patient-level proof, the story weakens.
Reconciling every source to the PMS at the appointment level is unglamorous work — and it is exactly what turns a growth narrative into an underwritable model.
Standardize before you scale
De novo and add-on integration go faster when the growth stack is one system with one definition of a new patient. Standardizing before the next three acquisitions is cheaper than reconciling six vendors afterwards.
